Background. Although tacrolimus is recommended by KDIGO Clinical Practice Guideline for Glomerulonephritis for the treatment of idiopathic membranous nephropathy (MN), little is known about factors that influence response and relapse of the disease after tacrolimus therapy. Methods. Multicentre study that collected 122 MN patients with nephrotic syndrome and stable renal function treated with tacrolimus. Duration of treatment was 17.6 ± 7.2 months, including a full-dose and a tapering period. Results. The percentage of remission was 60, 78 and 84% after 6, 12 and 18 months of treatment, respectively. The amount of proteinuria at baseline significantly predicted remission, the lower the baseline proteinuria the higher the probability of remission. Only 10 patients (8%) received concomitantly corticosteroids, and their rate of remission was similar (80% at 18 months). Among responders, 42% achieved complete remission (CR) and 58% partial remission (PR). Almost half (44%) of the responder patients relapsed. The amount of proteinuria at the onset of tacrolimus tapering was significantly higher in relapsing patients. By multivariable analysis, the presence of a PR versus CR at the onset of tacrolimus tapering and a shorter duration of the tapering period significantly predicted relapses. Tolerance was good and the number of adverse events low.
I N T R O D U C T I O N
KDIGO Clinical Practice Guideline for Glomerulonephritis recommends cyclical treatment with corticosteroids and cyclophosphamide as the first therapeutic option in patients with primary membranous nephropathy (MN) [1] . This recommendation is based on the proven efficacy of the Ponticelli regimen when compared with supportive treatment in several randomized controlled trials (RCT) [2] [3] [4] [5] . Calcineurin inhibitors (CNIs), either cyclosporine or tacrolimus, are stated as the second therapeutic option [1] . Cyclosporin plus low-dose corticosteroids induced a significantly higher number of remissions (69%) than placebo plus corticosteroids in an RCT [6] , although the number of relapses after cyclosporin discontinuation was remarkable (45%). A beneficial effect of cyclosporine when compared with placebo was observed in another RCT that included patients with massive proteinuria and deteriorating kidney function [7] . Cyclosporin doses, blood levels, and treatment duration associated to better outcomes in the management of MN have been analysed in several observational studies [8] [9] [10] [11] .
Regarding tacrolimus, an RCT using tacrolimus monotherapy (without corticosteroids) showed a probability of remission of 94% after 18 months of treatment when compared with 35% in a control group of patients who received only supportive therapy [12] . An important limitation of this trial was the small number of included patients (25 treated with tacrolimus and 23 in the control group). In contrast with cyclosporin, no large observational studies evaluating tacrolimus treatment in MN have been published. To know the real benefits and shortcomings of MN treatment with tacrolimus in common clinical practice, its side effects and those factors that could predict the appearance of remission and relapse, would provide important information for nephrologists.
Here, we present the results of a multicentre retrospective cohort study that collected 122 patients with biopsy-proven MN who were treated with tacrolimus.
M E T H O D S

Study design
The Scientific Committee of the Spanish Group for the Study of Glomerular Diseases designed an observational and longitudinal retrospective cohort study of patients with biopsy-proven MN treated with tacrolimus. Twelve centres agreed to participate in the study. Participating centres were required to include all of the biopsy-proven MN treated with tacrolimus, independently of their clinical characteristics or response to treatment. Patients having received the diagnosis of secondary MN were excluded.
Patients and data collection
One hundred and twenty-two patients were identified and included in the study. Clinical and analytical data were compiled from medical records at each participating centre using a uniform protocol. For each patient, the date of the onset of tacrolimus treatment was established as the baseline point. Events occurring during follow-up were recorded and analysed, including the appearance of CR or PR of the nephrotic syndrome, relapse of nephrotic syndrome, end-stage renal disease (ESRD) or death. Follow-up time was considered as the interval (in months) between the onset of tacrolimus therapy and the last outpatient visit, ESRD, death, onset of other immunosuppressive treatments or nephrotic syndrome relapse after tacrolimus withdrawal. Median follow-up was 30 months (14-66).
Tacrolimus
Mean initial doses of tacrolimus were 0.049 ± 0.01 mg/kg/day (0.04-0.06), divided in two daily doses at 12-h interval. Duration of tacrolimus treatment was 17.6 ± 7.2 months (12-18), including a full-dose period (12.5 ± 5.2 months, ranging from 9 to 15) and a tapering period (5.8 ± 4.3 months, ranging from 3 to 6) in which tacrolimus was gradually withdrawn. Mean blood through levels of tacrolimus, excluding the period of gradual tapering, were 6.8 ± 1.8 ng/mL (range 5.5-8). In those patients showing a 50% increase in baseline serum creatinine concentrations, tacrolimus doses were reduced by 25% every 2 weeks, and functional factors (excessive diuretic doses, low blood pressure) were carefully excluded. If serum creatinine persisted >50% of baseline values after >75% reduction of tacrolimus doses, tacrolimus was definitely withdrawn.
Outcomes
The primary outcome was the appearance of remission, either CR or PR. Secondary outcomes included the time to remission (either CR or PR), the appearance of relapses after tacrolimus discontinuation, duplication of baseline serum creatinine, ESRD and serious and non-serious side effects related with tacrolimus treatment.
Definitions
Nephrotic syndrome was defined by a proteinuria >3.5 g/day along with hypoalbuminaemia (serum albumin <3 g/dL). CR was defined by a proteinuria value of <0.3 g/24 h in at least three consecutive visits without concomitant renal function worsening. PR was defined by a proteinuria value of >0.3 but <3.5 g/day plus a 50% reduction from its peak value, in at least three consecutive visits, along with normal serum albumin and stable renal function (increase of serum creatinine <30% of baseline value). A relapse was defined by the reappearance of proteinuria >3.5 g/24 h in at least three consecutive visits. ESRD was defined by the need of chronic dialysis or having received a kidney transplant. Nephrotoxicity was defined by a serum creatinine increase >50% of baseline values after the exclusion and correction of functional factors.
Statistical analysis
Continuous variables with normal or symmetrical distribution were expressed as mean and SD. Otherwise, median and percentiles 25 and 75 (interquantile range) were used. Categorical variables were expressed as frequencies or percentages. Baseline differences between patients with or without remission (either partial or complete) were compared by the unpaired Student's t-test or Wilcoxon's rank-sum test for continuous variables and by likelihood χ 2 and Fisher's exact test for categorical variables. Primary and secondary outcomes were evaluated as proportion of events at the end of tacrolimus therapy and at the end of follow-up. Additionally, outcome probability as time to event was evaluated by univariate analysis with Kaplan-Meier curves and log-rank test, and by multivariate Cox's regression. We analysed the impact of baseline proteinuria on major outcomes as a continuous variable and as a categorical variable (by quartiles), to identify special high-risk groups for no remission of nephrotic syndrome or for renal function decline. Variables with P-values of <0.10 in univariate analysis and with biological plausibility to impact on major outcomes were introduced in multivariable Cox regression model by backward step. We evaluated potential correlations and interactions between baseline variables to avoid problems of collinearity.
Baseline factors associated with major outcomes were determined by Cox proportional hazard's model. The magnitude of association was expressed as hazard ratio (HR) with 95% confidence interval (95% CI). All end points were conducted at a two-tailed significance level of P < 0.05. The significance of the model was evaluated by change of logarithmic likelihood (−2 LogLL) and by Rao test (overall score).
R E S U LT S
Clinical characteristics
One hundred and twenty-two patients were identified and included in the study (Figure 1 ). The main clinical characteristics of included patients are summarized in Table 1 . Renal function was stable in all of them, no patient showing renal function decline in the 6-month period before tacrolimus onset. Twentythree patients (19%) had an eGFR <60 mL/min/1.73 m 2 at baseline, but it was >30 mL/min/1.73 m 2 in all the cases. All the patients showed a complete nephrotic syndrome at the onset of tacrolimus. Median interval between diagnosis (performance of renal biopsy) and onset of tacrolimus was 9 months (range 6-34). Forty-three patients (35%) had received previous immunosuppressive treatments, including corticosteroids, cyclophosphamide, chlorambucil and mycophenolate mofetil. A great majority of patients (94%, 115 patients) were receiving ACEI/ ARB treatment at the onset of tacrolimus. Only a minority of cases (10 patients, 8%) received concomitant treatment with corticosteroids. Initial doses of corticosteroids in these 10 patients were 0.8 ± 0.2 mg/kg/day and the mean duration of corticosteroid treatment 8 ± 4 weeks.
Renal biopsies showed Stage I of the disease in 37 patients (30%), Stage II in 62 (51%), Stage III in 22 (18%) and Stage IV in 1 (1%). The mean percentage of globally sclerosed glomeruli was 6.4 ± 9 (range 0-10). Tubulointerstitial fibrosis was observed in 34 (27%) of renal biopsies, mild in 28 (82%) and moderate in 6 (18%).
Median follow-up was 30 months (14-66). Follow-up was significantly shorter in patients without remission, since most of them received other immunosuppressive treatments. 
T a c r o l i m u s i n m e m b r a n o u s n e p h r o p a t h y Remission One hundred and three patients (84%) achieved remission of NS, either CR or PR, as shown in Table 1 . There were no significant differences at baseline between responder and nonresponder patients, although there was a non-significant tendency towards a higher proportion of women, better renal function, lower proteinuria and higher serum albumin among responders (Table 1) .
Patients without previous immunosuppressive treatments had a non-significant higher rate of remissions. There were no differences among responder and non-responder patients regarding the percentage of cases who received corticosteroids concomitantly with tacrolimus (7 and 10% respectively), and the interval between diagnosis (renal biopsy) and the onset of tacrolimus was very similar (Table 1) . No patient achieved remission after tacrolimus discontinuation.
Median time to PR was 6 (1-18) months and median time to CR 9 (1-96) months. As shown in Figure 2 , the percentage of nephrotic syndrome remission was 25% (CR 10%), 40% (CR 16%), 60% (CR 23%), 78% (CR 34%) and 84% (PR 42%) at 2, 4, 6, 12 and 18 months, respectively, after the onset of tacrolimus therapy.
By multivariable analysis (Table 2) , we found that the probability of remission was significantly lower in patients in the third and fourth (highest) quartiles of proteinuria, when compared with patients in the lowest quartile (Table 2) .
Complete remission
Forty-three of the 103 responder patients (42%) showed CR, and the remaining 60 patients (58%) showed PR. Main clinical and analytical characteristics of both CR and PR patients are shown in Table 3 . There was a significantly higher proportion of women among CR patients. At baseline, CR patients had a significantly higher renal function and lower proteinuria than PR patients. CR was significantly less common among patients previously treated with other immunosuppressive drugs. The appearance of a PR of nephrotic syndrome was significantly earlier among patients who later developed CR (Table 3) 
By multivariable analysis, as shown in Table 4 , female gender and proteinuria at baseline were the only predictive factors of a CR.
Relapses
As shown in Figure 1 , eight responder patients were lost to follow-up and 16 were still on tacrolimus treatment at the end of the study. Relapses were analysed in the remaining 79 responder patients who had discontinued tacrolimus. Median follow-up after tacrolimus withdrawal in these patients was 40 months (3-87). Nephrotic syndrome relapse occurred in 35/79 patients (44%). Median time to relapse since the onset of tacrolimus tapering was 9.5 (6-18) months. As shown in Figure 3 , the majority of relapses occurred during tacrolimus tapering (14 of 35 patients, 40% of relapses) or shortly after its discontinuation (21 of 35 patients, 60% of relapses). As shown in Table 5 , the amount of proteinuria and the number of patients on PR at the onset of tacrolimus tapering were significantly higher in relapsing patients. In addition, the occurrence of relapses was also significantly earlier in PR patients than in CR patients: 8.5 months (3-26) after the onset of tacrolimus tapering versus 20 months (6-62) (P = 0.024). By multivariable analysis, a PR at the onset of tacrolimus tapering and a F I G U R E 2 : Percentage of complete (black) and partial (white) remissions after the onset of tacrolimus treatment. F I G U R E 3 : Monthly incidence and cumulative number of relapses after the onset of tacrolimus tapering.
O R I G I N A L A R T I C L E
T a c r o l i m u s i n m e m b r a n o u s n e p h r o p a t h y shorter duration of tacrolimus tapering were factors significantly associated with relapses. By every additional month of tacrolimus tapering period, the probability of relapse decreased by 12% (Table 6) . Relapsing patients received different treatments (restartment of tacrolimus in 13, maintenance of tacrolimus at increased doses in 12, rituximab in 9 and mycophenolate mofetil in 1). At the end of follow-up, six patients (17%) had doubled their baseline serum creatinine and two patients (6%) had achieved ESRD.
Non-relapsing patients maintained stable renal function during follow-up. At the end of follow-up, none of them had doubled baseline serum creatinine nor achieved ESRD, and none received further immunosuppressive treatments. Nineteen patients (43%) were in CR and 25 patients were (57%) in PR at the end of follow-up.
Tolerance to tacrolimus and adverse events Tacrolimus was well tolerated and the number of serious adverse events was low. Adverse events are shown in Table 7 . Nephrotoxicity (≥50% increase in serum creatinine after the onset of tacrolimus treatment) was observed in eight (6%) patients, and in four of them renal function recovered its baseline values after adjustment of tacrolimus doses (see Methods). In the remaining four cases, tacrolimus was withdrawn because persistence of renal function impairment after dose adjustments.
Two patients required hospitalization because of urinary tract infections that were successfully treated without tacrolimus discontinuation. Four patients suffered serious cardiovascular events (myocardial infarction in 1, stroke in 3), likely unrelated with tacrolimus treatment and that were treated without tacrolimus withdrawal.
D I S C U S S I O N
Our study shows that tacrolimus induces remission of nephrotic syndrome in a high proportion (84%) of patients with MN. The percentage of remissions progressively increased after the onset of treatment: 25, 60, 78 and 84% after 2, 6, 12 and 18 months of treatment, respectively (Figure 2 ). Our study suggests that tacrolimus efficacy can be achieved without concomitant corticosteroid treatment: only 10 patients (8%) concomitantly received corticosteroids, and their rate of remission was similar (80%) to that of patients who did not receive corticosteroids. This finding is clinically relevant, considering that MN affects predominantly adult and elderly patients who are more sensitive to the wellknown side effects of corticosteroids [13] [14] [15] [16] [17] . On the other hand, tacrolimus doses and blood levels needed to achieve this remarkable number of remissions were relatively low. Mean doses and mean blood levels during the first year of therapy were 0.05 ± 0.01 mg/kg/day and 6.8 ± 1.8 ng/mL, respectively. We found that the amount of proteinuria at baseline was the only factor that significantly predicted the probability of remission, the lower the baseline proteinuria, the higher the probability of remission. The number of CR was significantly lower in patients gathering most of the classical factors associated with a worse prognosis in MN: male gender, lower renal function and higher proteinuria, as shown in Table 3 . By multivariable analysis, a lower baseline proteinuria and female gender, predicted the occurrence of CR (Table 4) .
Another important finding of the study was the good tolerance and the low number of important side effects related to tacrolimus therapy. Nephrotoxicity is a well-known side effect of CNI, but only four patients required tacrolimus discontinuation because this reason. Adverse events (listed in Table 7 ) were mild and did not require tacrolimus withdrawal.
The main shortcoming of tacrolimus treatment was the high number of relapses: almost half (44%) of our patients who had achieved CR or PR relapsed after tacrolimus discontinuation. Most of relapses appeared shortly after tacrolimus withdrawal or during the period of tacrolimus tapering. Previous studies with CNI in MN had pointed out this important tendency to relapse [6] [7] [8] [9] [10] [11] [12] 18] , but very little is known about those factors that could influence the reappearance of proteinuria after drug withdrawal. We found that the amount of proteinuria at the onset of tacrolimus tapering was significantly higher in relapsing patients, and that the occurrence of relapses was significantly earlier in patients with a PR when compared with those with a CR. By multivariable analysis, the presence of a PR versus CR at the onset of tacrolimus tapering and a shorter duration of tacrolimus tapering were factors significantly associated with relapses by multivariable analysis. These findings are important for clinical practice, suggesting that a more extended period of tacrolimus tapering should be considered for those patients showing the highest amounts of proteinuria within the PR range (>0.3 and <3.5 g/day) at the onset of tacrolimus tapering.
Therapeutic options for those patients who show a relapse during or after tacrolimus tapering have been scarcely investigated. A possible option could be to restart tacrolimus and maintain it for longer periods, but the risk of chronic nephrotoxicity, as observed in nephrotic patients treated with cyclosporine [10] , or the appearance of other side effects associated with chronic tacrolimus treatment such as diabetes or infections are serious concerns. Another possibility is rituximab: our group reported in a previous study of 13 MN patients with a clear CNIdependence (several recurrences of nephrotic syndrome after CNI withdrawal) in whom CNI could be discontinued after receiving rituximab [19] . On the other hand, several non-controlled studies have reported a very promising profile of rituximab in the treatment of MN [20] [21] [22] . The STARMEN study (NCT01955187 Clinicaltrials.gov) will prospectively compare the classical Ponticelli regimen (corticosteroids and cyclophosphamide for 6 months) versus tacrolimus for 9 months (6 months of full therapy and 3 months of tapering doses) and rituximab (1 g before the onset of tacrolimus tapering) and can provide important information about the efficacy of rituximab to prevent relapses. A prospective RCT failed to demonstrate a preventive effect of mycophenolate mofetil administered during tacrolimus tapering in MN [18] .
Another finding of the study that is worthwhile stressing is the excellent outcome of those patients who did not relapse after tacrolimus discontinuation. At the end of follow-up, 43% had CR and 57% PR. None of them had doubled baseline serum creatinine nor achieved ESRD, and none received further immunosuppressive treatments. Therefore, tacrolimus monotherapy is a very effective and safe treatment for those patients who did not relapse after its discontinuation.
All included patients had nephrotic-range proteinuria and hypoalbuminaemia at the onset of tacrolimus therapy. None of them had shown a tendency to spontaneous proteinuria decrease or renal function improvement in the year preceding tacrolimus treatment, in spite of ACEI/ARB treatment in almost all the patients (94%). Therefore, the possibility of spontaneous remission appeared unlikely in our patients and this was the main reason to indicate tacrolimus treatment. It should be stressed that our study included patients with stable renal function during the 6-month period before treatment. These data are relevant because a recent RCT that compared corticosteroids plus cyclosporin, corticosteroids plus chlorambucil and supportive therapy in patients with MN and declining renal function showed that patients treated with corticosteroids plus chlorambucil had the better outcomes [23] . Other observational studies [14] [15] [16] have also suggested that Ponticelli's regimen is the most effective therapy for patients with deteriorating renal function.
Very few studies have compared CNI with corticosteroids plus alkylating agents in the treatment of MN. A retrospective study showed a higher rate of remissions and less side effects using corticosteroids plus cyclosporin compared with corticosteroids plus alkylating drugs [24] . A significantly higher remission rate at 6 months among patients treated with tacrolimus was found in an RCT that compared tacrolimus with cyclophosphamide [25] . Both groups received corticosteroids. However, there were no significant differences at 1 year and no information was provided about relapses after drug discontinuation.
It has been shown that the titer of antibodies against the M-type phospholipase A2 receptor (anti-PLA2R) has a significant correlation with the clinical activity and the response to immunosuppressive treatments (mainly corticosteroids plus cyclophosphamide and rituximab) in MN [14] . A recent study has shown that anti-PLA2R monitoring is also useful and predicts remission in MN patients treated with tacrolimus monotherapy [26] . Unfortunately, blood sampling for anti-PLA2R was not routinely performed in our patients.
In conclusion, our data suggest that tacrolimus monotherapy is an efficient alternative for MN patients, particularly in those with stable renal function, providing a high remission rate without important side effects. Once remission is achieved, the presence of a PR should alert about the risk of relapse after tacrolimus withdrawal, the higher the residual proteinuria, the higher the risk of relapse. In these patients, an extended period of tacrolimus tapering, >6 months, or a cycle of rituximab preceding tacrolimus tapering [19] , could diminish the risk of relapses, although prospective controlled studies are needed to corroborate these issues.
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